Wunderman adds new role to its shop

Share this article:
Wunderman has hired Ira Haimowitz for the newly created role of group director, data
strategy.

Haimowitz will be based out of Wunderman's New York headquarters, and report to Mark Taylor, EVP and chief marketing technology officer.

Haimowitz told MM&M, “My role entails being a leader to deliver insight, metrics and optimization to our clients, helping them understand their customers better and helping them evaluate the impact of the relationship marketing programs Wunderman delivers.”

Haimowitz joins Wunderman from Organon Pharmaceuticals, where he spent the previous year-and-a-half. Prior to that, he was with Pfizer for eight years and General Electric Research and Development for four years. At these companies Haimowitz helped to spearhead efforts for marketing and sales analytics, for both the consumer and business sectors, he said.

“For the past 13 years, I have been on the client side,” he explained. “Now I am now trying to take all the solutions I have learned as a leader and deliver them out to the whole marketplace. I am definitely excited about doing that.” he said. “I think I can help our clients better leverage and understand who their customers are by doing segmentation, so they can develop targeted campaigns, experimental designs and understand what offers and creative will work in the marketplace.”

Haimowitz holds a PhD in computer science from the Massachusetts Institute of Technology. He has served for seven years on the Board of the Pharmaceutical Management Science Association, including as the group's president in 2006.

Wunderman's recent pharma clients include Novartis, Bayer, Pfizer and AstraZeneca. Wunderman's RTCRM unit does work for Abbott Laboratories, Sanofi-Aventis, Bayer's Berlex Labs, and the Bayer, Schering-Plough and GlaxoSmithKline jointly marketed Levitra.

Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.